Immunization Programs

What makes immunisation a public programme?

An immunisation programme turns an effective vaccine into an accessible, reliable preventive service. It must identify eligible people, obtain and store supplies, organise trained staff, record doses, arrange follow-up and monitor safety. A vaccine's availability at a central store does not establish that a child in a remote settlement can receive the appropriate service. The programme is therefore both a biomedical intervention and a delivery system.

Vaccination is the administration of a vaccine; immunisation concerns the protection developed through the immune response. Programme performance also depends on the particular vaccine, schedule and population. It is misleading to treat the number of doses supplied as the number of people fully protected. The UPSC governance question is how policy, logistics, trust and measurement connect, rather than how to prescribe an individual clinical schedule.

Which historical milestones organise the Indian framework?

India's Expanded Programme on Immunization began in 1978 and became the Universal Immunization Programme in 1985. Mission Indradhanush was launched in December 2014 to reach unvaccinated and partially vaccinated children, particularly in low-coverage and hard-to-reach areas. A catch-up effort complements routine services; it does not remove the need for regular sessions, reliable supplies and follow-up between campaigns.

Date the source before repeating a programme inventory. An older official webpage can retain language about a vaccine awaiting national expansion even after the expansion has occurred. Historical launch information can remain useful while that operational description becomes stale. The safer reading is to separate stable institutional history from the latest schedule and dated implementation reports. A website's recent footer date is not proof that every paragraph has been substantively updated.

What does reaching a missed child require?

Low uptake can reflect distance, inconvenient timing, mobility, missing information, stock-outs or concerns about vaccination. These are different barriers and require different responses. More publicity may help where information is missing, but it cannot substitute for an unavailable session. An outreach session may reduce travel costs, while respectful communication and reliable follow-up can address other obstacles. Diagnose the reason before choosing an intervention.

WHO and UNICEF operationally measure zero-dose children through absence of a first dose of a DTP-containing vaccine. This is a useful proxy for being missed by routine services, not a statement that an investigator has individually checked every possible vaccine. A child who received the first dose but missed later doses presents a different continuity problem. The distinction helps planners separate initial access from completion of the relevant series.

How should coverage and dropout be calculated?

Coverage needs a clearly defined numerator and eligible denominator. In a hypothetical cohort of 1,000 eligible children, 900 receive a first dose and 810 receive a third dose. First-dose coverage is 90 per cent and third-dose coverage is 81 per cent. Dropout from the first to the third dose is the difference, 90, divided by the 900 who started: 10 per cent. The nine-percentage-point coverage gap is a different quantity.

The example assumes the same cohort and reliable records. If people move, eligibility estimates change or doses are duplicated, a simple comparison can mislead. Administrative reporting, household surveys and modelled estimates may use different methods. High national coverage can also conceal poorly served localities. Programme review should inspect geography and social access alongside the overall percentage, rather than interpret an average as proof of universal reach.

Why are supply information and beneficiary records different?

Cold-chain management protects vaccine quality through appropriate storage and transport. Stock records help prevent shortages and wastage; temperature information helps identify handling problems. NHM describes eVIN as a system for vaccine-stock and temperature tracking. A stock-management system answers whether supplies are available and appropriately managed, not whether a particular child completed the doses due.

U-WIN, nationally launched on 29 October 2024, records vaccination events under UIP and supports beneficiary tracking. The two functions are complementary. Digital records can help continuity across locations, but they need accurate entry, usable access and arrangements for people requiring assistance.

A completed electronic entry is evidence of recording; service quality and safety require their own checks. Digitalisation should reduce the burden on families rather than create a new administrative reason for exclusion.

How should safety information be interpreted?

An adverse event following immunisation is a medical occurrence after immunisation; the timing alone does not establish that the vaccine caused it. AEFI surveillance requires reporting, timely response and assessment of possible causes. Dismissing an event without inquiry and declaring causation from sequence alone are both poor reasoning. The programme must protect the person affected while examining the evidence carefully.

Communication should preserve this distinction in language a family can understand. A safety system is part of a trustworthy programme, not evidence that reporting itself undermines vaccination. Staff need a clear response pathway and communities need credible information. For an examination answer, explain the surveillance function and the difference between association and causation; do not turn a governance discussion into unsupported advice about an individual's medical circumstances.

What changed in 2026, and what would demonstrate success?

The Health Ministry records the launch of a nationwide HPV vaccination campaign on 28 February 2026 for eligible girls aged fourteen. Its 11 September 2026 release reports more than eighty lakh doses administered since launch and describes the programme as free and voluntary.

These are dated programme facts. A dose milestone is not a direct measurement of future cancer incidence, and a campaign's target population should not be confused with everyone who might benefit clinically from vaccination.

Evaluate immunisation through timely access, continuity, equitable coverage, reliable logistics and safety response. Connect each problem to an operational remedy and a suitable indicator. The strongest conclusion is that a vaccine programme succeeds when people can receive the intended preventive service reliably, with the recording and public-health systems capable of finding and correcting the gaps.